Edward Wynell Thomas

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK.

Nasdaq Clearing AB conducts authorized clearing operations for exchange traded, repo clearing, and over-the-counter contracts. It offers its services to the following asset classes: share and index derivatives, fixed-income derivatives, commodities, Fish, repo contracts, and OTC transactions outside the exchange. The company is headquartered in Stockholm, Sweden.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.

Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.

Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions.

Velo Payments, Inc. provides APIs and web portals for businesses to make payments. The private company was founded by John Davies and is currently based in Sausalito, CA. The company's strategic payment solutions cater to both small businesses and large enterprises, offering enhanced visibility, efficiency, and flexibility to each payment. The CEO is John M. Partridge.